JP6657089B2 - 関節リウマチを治療するための組成物およびこれを使用する方法 - Google Patents

関節リウマチを治療するための組成物およびこれを使用する方法 Download PDF

Info

Publication number
JP6657089B2
JP6657089B2 JP2016533206A JP2016533206A JP6657089B2 JP 6657089 B2 JP6657089 B2 JP 6657089B2 JP 2016533206 A JP2016533206 A JP 2016533206A JP 2016533206 A JP2016533206 A JP 2016533206A JP 6657089 B2 JP6657089 B2 JP 6657089B2
Authority
JP
Japan
Prior art keywords
weeks
subject
treatment
antibody
salilumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539125A5 (enExample
JP2016539125A (ja
Inventor
ジャオハン・ファン
マルティーヌ・ジェソン
ヴァネサ・マルクス
アレン・ラディン
シュンペン・ファン
ヒューバート・ヴァン・ホッグストラティン
ステファノ・フィオーレ
ジャネット・ヴァン・アデルズバーグ
マーク・ジェノヴェーゼ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016539125A publication Critical patent/JP2016539125A/ja
Publication of JP2016539125A5 publication Critical patent/JP2016539125A5/ja
Application granted granted Critical
Publication of JP6657089B2 publication Critical patent/JP6657089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016533206A 2013-11-22 2014-11-21 関節リウマチを治療するための組成物およびこれを使用する方法 Active JP6657089B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US61/907,796 2013-11-22
US201462008787P 2014-06-06 2014-06-06
US62/008,787 2014-06-06
EP14306366.7 2014-09-05
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019209255A Division JP2020045351A (ja) 2013-11-22 2019-11-20 関節リウマチを治療するための組成物およびこれを使用する方法

Publications (3)

Publication Number Publication Date
JP2016539125A JP2016539125A (ja) 2016-12-15
JP2016539125A5 JP2016539125A5 (enExample) 2017-12-28
JP6657089B2 true JP6657089B2 (ja) 2020-03-04

Family

ID=51518724

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016533206A Active JP6657089B2 (ja) 2013-11-22 2014-11-21 関節リウマチを治療するための組成物およびこれを使用する方法
JP2021196599A Pending JP2022033891A (ja) 2013-11-22 2021-12-03 関節リウマチを治療するための組成物およびこれを使用する方法
JP2023202342A Pending JP2024026223A (ja) 2013-11-22 2023-11-30 関節リウマチを治療するための組成物およびこれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021196599A Pending JP2022033891A (ja) 2013-11-22 2021-12-03 関節リウマチを治療するための組成物およびこれを使用する方法
JP2023202342A Pending JP2024026223A (ja) 2013-11-22 2023-11-30 関節リウマチを治療するための組成物およびこれを使用する方法

Country Status (11)

Country Link
US (1) US20160280782A1 (enExample)
EP (2) EP3770173A1 (enExample)
JP (3) JP6657089B2 (enExample)
KR (3) KR20230155586A (enExample)
CN (2) CN106413748A (enExample)
AU (3) AU2014352801B2 (enExample)
CA (1) CA2930615C (enExample)
MX (2) MX377190B (enExample)
PL (1) PL3071230T3 (enExample)
SG (1) SG10201804000TA (enExample)
WO (1) WO2015077582A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
WO2015077582A1 (en) * 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
KR20180073680A (ko) 2015-11-03 2018-07-02 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법
SG11201807614SA (en) * 2016-03-07 2018-10-30 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
US12295912B2 (en) 2017-12-07 2025-05-13 Zacros Corporation Port-equipped bag and cap-equipped bag
JP7504871B2 (ja) * 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
AU2020216978B2 (en) * 2019-01-31 2025-09-25 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
MA55760A (fr) * 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
BR112021024445A2 (pt) * 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
ES2799439T3 (es) * 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
WO2015077582A1 (en) * 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
AU2024204881A1 (en) 2024-08-15
CA2930615A1 (en) 2015-05-28
CN106413748A (zh) 2017-02-15
EP3770173A1 (en) 2021-01-27
CN120514847A (zh) 2025-08-22
SG10201804000TA (en) 2018-07-30
JP2022033891A (ja) 2022-03-02
KR20220056254A (ko) 2022-05-04
KR20160079121A (ko) 2016-07-05
AU2020223706A1 (en) 2020-09-10
MX2020011993A (es) 2021-01-29
US20160280782A1 (en) 2016-09-29
MX2016006595A (es) 2016-09-06
EP3071230A1 (en) 2016-09-28
KR20230155586A (ko) 2023-11-10
AU2020223706B2 (en) 2024-04-18
MX377190B (es) 2025-03-07
CA2930615C (en) 2023-04-04
AU2014352801B2 (en) 2020-05-28
EP3071230B1 (en) 2020-04-08
JP2016539125A (ja) 2016-12-15
WO2015077582A1 (en) 2015-05-28
AU2014352801A1 (en) 2016-06-23
PL3071230T3 (pl) 2020-09-21
JP2024026223A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP6657089B2 (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
JP7025477B2 (ja) 関節リウマチを治療するための組成物およびこれを用いる方法
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
HK40044249A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP2021167333A (ja) 関節リウマチを治療するための組成物およびこれを用いる方法
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1195495B (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1195495A (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200205

R150 Certificate of patent or registration of utility model

Ref document number: 6657089

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250